News
-
Bausch Health announced that Health Canada has approved a clinical trial of the company’s Virazole ribavirin inhalation solution for the treatment of respiratory distress in patients hospitalized with COVID-19, and the study is expected to… Read more . . .
-
Organizers for the Drug Delivery to the Lungs (DDL) meetings say that they are provisionally moving ahead with DDL 2020, scheduled for December 9-11 at the Edinburgh International Conference Centre, and they have issued a… Read more . . .
-
Finnish nanoparticle engineering company Nanoform has announced the beginning of a year-long process that will conclude with Miguel Calado succeeding Rabbe Klemets as Chairman of the Board. Klemets will take on an advisory role. Calado… Read more . . .
-
Aerosol testing specialist Proveris Scientific has announced two new hires: Lee Dalton has joined Proveris as Director of Sales for North America, and Juan Osvaldo Moliere Velez, a mechanical engineer, has joined the company’s technical… Read more . . .
-
Biohaven Pharmaceutical said that the FDA has approved the company’s IND for a Phase 2 study of its vazegepant intranasal calcitonin gene-related peptide (CGRP) receptor antagonist for the reduction of excessive immune response leading to… Read more . . .
-
Theravance Biopharma said that it has submitted a clinical trial application (CTA) to begin clinical development of its TD-0903 nebulized JAK inhibitor for prevention of cytokine storm, which can lead to acute respiratory distress syndrome… Read more . . .
-
TFF Pharmaceuticals has announced a research collaboration deal with the University of Georgia’s Center for Vaccines and Immunology (CVI) and with the University of Texas at Austin (UT Austin) for testing of dry powder universal influenza vaccines formulated using TFF’s… Read more . . .
-
Cipla has announced that a Phase 3 study demonstrated therapeutic equivalence of its generic fluticasone propionate/salmeterol DPI (100/50 mcg) to Advair Diskus 100/50 mcg. The 15-month trial enrolled 1400 asthma patients in the US. Cipla… Read more . . .
-
The FDA has announced its approval of a Cipla albuterol sulfate MDI, a generic of 3M’s Proventil HFA for the treatment of asthma. The FDA announcement noted that the agency recently issued a revised draft… Read more . . .
-
Liquidia Technologies said that the FDA accepted the company’s 505(b)(2) NDA for its LIQ861 treprostinil DPI for the treatment of pulmonary arterial hypertension (PAH), with a PDUFA goal date of November 24, 2020. The company announced in… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.